Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 6710 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
2. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
3. Cita con resumen
4. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
5. Cita con resumen
Mudd PA, Thottathil P, Giordano T, Wetmore RF, Elden L, Jawad AF, Ahumada L, Gálvez JA. Association between ibuprofen use and severity of surgically managed posttonsillectomy hemorrhage. JAMA Otolaryngol Head Neck Surg 2017:4 de mayo. [Ref.ID 101564]
6. Cita con resumen
7. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
10. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
11. Cita con resumen
Anónimo. Litigation is new tactic in opioid crisis. DIA Daily 2017:1. [Ref.ID 101500]
14. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
15. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
16. Cita con resumen
Anónimo. Griflozines: insuffisances rénales. Prescrire 2017;37:105. [Ref.ID 101443]
17. Cita con resumen
19. Cita con resumen
Anónimo. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017;59:22-3. [Ref.ID 101421]
20. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
Seleccionar todas
 
 1 a 20 de 6710 siguiente >>